Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCM-R with Pegfilgrastim in Frontline CLL
NCT00254410Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2005
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, fludarabine, cyclophosphamide and mitoxantrone in chronic lymphocytic leukemia (CLL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Clinical Response Rate at 3 Months and Clinical Response Rate at 6 Months. Started Mar 2005; status: completed.
02
Drugs
rituximabfludarabinecyclophosphamidemitoxantrone
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00254410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00254410.